{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:46:13Z","timestamp":1792039573448,"version":"4.4.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.pcad.2026.10.004","type":"journal-article","created":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:08:38Z","timestamp":1791756518000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors affecting serum neurofilament light chain in transthyretin amyloid cardiomyopathy"],"prefix":"10.1016","author":[{"given":"Bryton","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israt","family":"Jahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey","family":"Volk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Chahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.pcad.2026.10.004_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073770","article-title":"Neurofilament light chains in systemic amyloidosis: a systematic review","volume":"25","author":"Berends","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.pcad.2026.10.004_bb0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.48593","article-title":"Types and concentrations of blood-based biomarkers in adults with peripheral neuropathies","volume":"5","author":"Fundaun","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.pcad.2026.10.004_bb0015","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-60025-6","article-title":"Neurological affection and serum neurofilament light chain in wild type transthyretin amyloidosis","volume":"14","author":"Pernice","year":"2024","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.pcad.2026.10.004_bb0020","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.neurol.2025.06.007","article-title":"Description of peripheral nervous system involvement in wild-type transthyretin amyloidosis: a clinical and electrophysiological study","volume":"181","author":"Barriol","year":"2025","journal-title":"Rev Neurol (Paris)"},{"issue":"1","key":"10.1016\/j.pcad.2026.10.004_bb0025","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10072-022-06459-0","article-title":"Peripheral nerve involvement in wild-type transthyretin amyloidosis","volume":"44","author":"Campagnolo","year":"2023","journal-title":"Neurol Sci"},{"key":"10.1016\/j.pcad.2026.10.004_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1345608","article-title":"Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center's experience","volume":"11","author":"\u017divkovi\u0107","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"10.1016\/j.pcad.2026.10.004_bb0035","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.pcad.2026.10.004_bb0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s42466-020-00064-2","article-title":"Diagnosis of peripheral neuropathy","volume":"2","author":"Lehmann","year":"2020","journal-title":"Neurol Res Pract"},{"issue":"4","key":"10.1016\/j.pcad.2026.10.004_bb0045","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.pcad.2026.10.004_bb0055","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/13506129.2023.2187678","article-title":"Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis","volume":"30","author":"Sato","year":"2023","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.pcad.2026.10.004_bb0060","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/jns.12524","article-title":"Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin-related amyloidosis\u2014a Swiss reference center experience","volume":"28","author":"Loser","year":"2023","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.pcad.2026.10.004_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1457984","article-title":"Negative association of serum neurofilament light chain with estimated glomerular filtration rate levels and the impact of gender","volume":"15","author":"Peng","year":"2024","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.pcad.2026.10.004_bb0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12882-025-04130-2","article-title":"Plasma concentrations of neurofilament light, p-Tau231 and glial fibrillary acidic protein are elevated in patients with chronic kidney disease and correlate with measured glomerular filtration rate","volume":"26","author":"Axelsson","year":"2025","journal-title":"BMC Nephrol"},{"issue":"14","key":"10.1016\/j.pcad.2026.10.004_bb0075","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025910","article-title":"Serum neurofilament light chain in patients with atrial fibrillation","volume":"11","author":"Sj\u00f6lin","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.pcad.2026.10.004_bb0076","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jchf.2024.03.005","article-title":"Serum markers of neurodegeneration are\u00a0strongly linked to heart\u00a0failure severity and outcome","volume":"12","author":"Wurm","year":"2024","journal-title":"JACC Heart Fail"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062026001131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062026001131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:04:12Z","timestamp":1792037052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062026001131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":15,"alternative-id":["S0033062026001131"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2026.10.004","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors affecting serum neurofilament light chain in transthyretin amyloid cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2026.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}